This trial is active, not recruiting.

Condition acute lymphoblastic leukemia, in relapse
Treatments graspa, l-asparaginase
Phase phase 2/phase 3
Sponsor ERYtech Pharma
Start date December 2009
End date September 2014
Trial size 80 participants
Trial identifier NCT01518517, GRASPALL2009-06


Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also neutralize asparaginase without any clinical signs of hypersensitivity (silent inactivation). GRASPA improves pharmacokinetics, tolerability and maintain circulating asparaginase activity due to the protective barrier of the erythrocyte membrane.

This study is run to confirm the benefit/risk profile of GRASPA at 150 IU/kg in combination with the COOPRALL regimen in adults and children patients with relapsed ALL, with or without known hypersensitivity to L-asparaginase.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL). GRASPA® administration takes place as below: for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity) for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)
graspa ERY001
one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
(Active Comparator)
For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL). •for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks). NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity) •for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles).
l-asparaginase KIDROLASE
3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy

Primary Outcomes

efficacy and toxicity combined
time frame: 1 month

Secondary Outcomes

Molecular response rate
time frame: 1 month
Plasma concentration of asparagine, aspartate, glutamine, glutamate and asparaginase
time frame: 0,1,3,6, 9 days post-dose
Specific anti L-asparaginase antibodies
time frame: 0,10 days post-dose
Event free survival
time frame: 6 and 12 month
Relapse free survival
time frame: 6 and 12 month
Overall survival
time frame: 6 and 12 month
Percentage of patient with complete remission
time frame: 1 month

Eligibility Criteria

Male or female participants from 1 year up to 55 years old.

Inclusion Criteria: - Patient from 1 to 55 years old (Children and adolescents from 1 to 17 years/ Adults from 18 to 55 years) - Patients with 1st ALL relapse, which could be either isolated bone marrow relapse, or combined (medullary and extra-medullary) relapse, or extra-medullary isolated relapse; or lymphoblastic lymphoma (excepted Burkitt lymphoma) OR Failure to ALL first line treatment (no complete remission obtained) - Patient previously treated with free E.Coli L-asparaginase form or pegylated one - Performance Status ≤ 2 (WHO score) - Patient informed and consent provided (the 2 parents need to consent when children are below 18) Exclusion Criteria: - ALL t(9;22) and/or BCR-ABL positive (Philadelphia chromosome positive) - Patient with 2nd relapse and over - Women of childbearing potential without effective contraception as well as pregnant or breast feeding women - Patient unable to receive treatments used in global chemotherapy protocols, due to general or visceral conditions such as:Severe cardiac impairment (NYHA grade 3 or 4 cardiomyopathy)/Serum creatinine 2 x ULN unless related to ALL /ALT or AST 5 x ULN unless related to ALL /Pancreatitis history /Other malignancy that ALL / Severe Infection, HIV positive, active hepatitis related to B or C virus infection / Trisomy 21 / Other serious conditions according to investigator's opinion - Known grade 4 allergic reaction to E.Coli L-asparaginase (according NCI-CTCAE, Version 3.0) - History of grade 3 transfusional incident - Presence of specific anti-erythrocyte antibodies preventing from getting a compatible erythrocyte concentrate for the patient - Patient under concomitant treatment likely to cause hemolysis - Patient undergoing yellow fever vaccination - Patient under phenytoin treatment - Patient included in previous clinical study less than 6 weeks ago

Additional Information

Official title Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia
Principal investigator Yves Bertand, MD
Description This open, randomized international Phase 2/3 study will enrol patients with relapsed ALL. The co-primary endpoints were the duration of asparagine depletion < 2µmol/L and the incidence of asparaginase hypersensitivity during induction. Key secondary endpoints are complete remission (CR), minimal residual disease (MRD), event free survival (EFS) and overall survival (OS).The study was powered to detect 3-fold difference in the incidence of allergic reactions between treatments. patients will be randomized to GRASPA or to Reference L-asparaginase. Patients with history of hypersensitivity to previous L-asparaginase treatment will be treated with GRASPA (exploratory arm)
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by ERYtech Pharma.